REGN2810/chemo/ipi

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Non-small Cell Lung Cancer

Phase 3

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

CompletedNCT03409614

Regeneron PharmaceuticalsNon-small Cell Lung Cancer

Start: 2018-03-06End: 2025-02-27Updated: 2025-03-13

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

TerminatedNCT03515629

Regeneron PharmaceuticalsNon-small Cell Lung Cancer

Start: 2018-07-02End: 2021-07-29Updated: 2022-11-16

Related Papers

Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy

Cancers2026-03-12

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial.

2024-05-138 citations

64P Patient-reported outcomes (PROs) of cemiplimab (CEMI) + platinum doublet chemotherapy (CHEMO) + ipilimumab (IPI) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-lung 3 part 1

ESMO Open2024-03-01

75P Patient-reported outcomes (PROs) of cemiplimab + chemotherapy in advanced non-small cell lung cancer (NSCLC): EMPOWER-lung 3 liver metastases subpopulation

Immuno-Oncology Technology2023-12-012 citations

Cemiplimab + Chemo Shows Clinical Benefit in Advanced NSCLC

Oncology Times2023-06-201 citations

Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.

Journal of Clinical Oncology2023-06-011 citations

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.

2023-03-2965 citations

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.

2022-08-25216 citations

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from a phase I dose escalation and NSCLC expansion cohort.

Journal of Clinical Oncology2019-03-105 citations

Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, in patients with non-small cell lung cancer (NSCLC): Interim data from phase 1 dose escalation and NSCLC Expansion Cohort.

Journal of Clinical Oncology2018-05-205 citations